Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

Lipid Regulating Agents

All Drugs and Chemicals

Coagulants

Bone Density Conservation Agents

Rosuvastatin Calcium

Thromboplastin

Calcium

Calcium, Dietary

Anticholesteremic Agents

Hypolipidemic Agents

Antimetabolites

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Enzyme Inhibitors

Rosuvastatin 20mg taken orally once a day for 4 weeks

Rosuvastatin 40mg taken orally once a day for 4 weeks

rosuvastatin

Jeffrey I. Zwicker, MD

Research studies have shown a strong association between cancer and blood clots in the veins (also known as deep vein thrombosis). These blood clots can flow to the lungs (pulmonary embolism) which in severe cases may be life threatening. Studies have demonstrated that increases in microparticles may contribute to the development of deep vein thrombosis in cancer patients. The purpose of this research study is to see if rosuvastatin lowers the number of tissue factor bearing microparticles in the blood (TFMP). TFMP are small particles that are generated from different types of blood cells in the body. In people who have cancer, TFMP are thought to be generated from cancer cells and may represent a risk factor for deep vein thrombosis.

* Since no one knows which of the study options are best, participants will be "randomized" into the following study groups: Group 1 (regular dose of rosuvastatin) or Group 2 (higher dose of rosuvastatin).
* Participants will take 1 pill of rosuvastatin every day for 4 weeks. Each 4 week period is called a cycle.
* Participants will have a physical exam at baseline, on day 1 of starting rosuvastatin, and 2 month visits. Laboratory tests will be taken at baseline, on day 1 of starting rosuvastatin, 6 weeks and 2 months.

Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer

A Multi-dose Phase II Trial of Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer

Comparison of plasma microparticle concentration between baseline and week 4

Dana-Farber Cancer Institute

Massachusetts General Hospital

National Institutes of Health (NIH)

Beth Israel Deaconess Medical Center

Assistant Professor, Harvard Medical School

Rosuvastatin 20mg taken orally once a day for 4 weeks

rosuvastatin: Taken orally once a day for 4 weeks

Rosuvastatin 20mg

Rosuvastatin 40mg taken orally once a day for 4 weeks

rosuvastatin: Taken orally once a day for 4 weeks

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer	NCT01299038	Breast Cancer	rosuvastatin	18 Years -	Dana-Farber Cancer Institute
Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer	NCT01299038	Breast Cancer	rosuvastatin	18 Years -	Dana-Farber Cancer Institute

Spots Global Cancer Trial Database for tfbp

Every month we try and update this database with for tfbp cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for tfbp

Every month we try and update this database with for tfbp cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for tfbp cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.